ImmunityBio Inc. (IBRX)
ImmunityBio Statistics
Share Statistics
ImmunityBio has 882.47M shares outstanding. The number of shares has increased by 23.41% in one year.
| Shares Outstanding | 882.47M |
| Shares Change (YoY) | 23.41% |
| Shares Change (QoQ) | 16.88% |
| Owned by Institutions (%) | 11.87% |
| Shares Floating | 91.8M |
| Failed to Deliver (FTD) Shares | 6.91K |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 63.18M, so 7.16% of the outstanding shares have been sold short.
| Short Interest | 63.18M |
| Short % of Shares Out | 7.16% |
| Short % of Float | 18.19% |
| Short Ratio (days to cover) | 10.12 |
Valuation Ratios
The PE ratio is -4.32 and the forward PE ratio is -7.06. ImmunityBio's PEG ratio is 0.09.
| PE Ratio | -4.32 |
| Forward PE | -7.06 |
| PS Ratio | 121.07 |
| Forward PS | 0.9 |
| PB Ratio | -3.66 |
| P/FCF Ratio | -4.48 |
| PEG Ratio | 0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ImmunityBio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of -0.09.
| Current Ratio | 3.36 |
| Quick Ratio | 3.21 |
| Debt / Equity | -0.09 |
| Debt / EBITDA | -0.16 |
| Debt / FCF | -0.11 |
| Interest Coverage | -2.61 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $21.68K |
| Profits Per Employee | $-608.18K |
| Employee Count | 680 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -49.39% in the last 52 weeks. The beta is -0.13, so ImmunityBio's price volatility has been lower than the market average.
| Beta | -0.13 |
| 52-Week Price Change | -49.39% |
| 50-Day Moving Average | 2.97 |
| 200-Day Moving Average | 3.85 |
| Relative Strength Index (RSI) | 42.83 |
| Average Volume (20 Days) | 6.44M |
Income Statement
In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.
| Revenue | 14.74M |
| Gross Profit | 14.74M |
| Operating Income | -344.18M |
| Net Income | -413.56M |
| EBITDA | -264.43M |
| EBIT | -281.99M |
| Earnings Per Share (EPS) | -0.59 |
Balance Sheet
The company has 143.43M in cash and 42.29M in debt, giving a net cash position of 101.14M.
| Cash & Cash Equivalents | 143.43M |
| Total Debt | 42.29M |
| Net Cash | 101.14M |
| Retained Earnings | -3.38B |
| Total Assets | 382.93M |
| Working Capital | 129.64M |
Cash Flow
In the last 12 months, operating cash flow was -391.24M and capital expenditures -6.89M, giving a free cash flow of -398.12M.
| Operating Cash Flow | -391.24M |
| Capital Expenditures | -6.89M |
| Free Cash Flow | -398.12M |
| FCF Per Share | -0.57 |
Margins
Gross margin is 100%, with operating and profit margins of -2334.23% and -2804.77%.
| Gross Margin | 100% |
| Operating Margin | -2334.23% |
| Pretax Margin | -2804.77% |
| Profit Margin | -2804.77% |
| EBITDA Margin | -1793.37% |
| EBIT Margin | -2334.23% |
| FCF Margin | -2700.06% |
Dividends & Yields
IBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IBRX is $8, which is 220% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 220% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -12.82 |
| Piotroski F-Score | 4 |